WFH NETWORK

Achievement of Normal FVIII Activity Following Gene Transfer with Valoctocogene Roxaparvovec (BMN 270): Long-Term Efficacy and Safety Results in Patients with Severe Hemophilia A

 
Details

Year: 2018

Language: English

Author(s): John Pasi

View Online
Additional Information

In the Tuesday morning session entitled Free Papers – Gene Therapy, John Pasi presents results of the BMN 270-201 Phase 1/2 dose escalation hemophilia A clinical trial.